Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Phone970-493-7272
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$127.45 million
Profitability
Miscellaneous
Employees347
Next Earnings Date11/5/2019 (Estimated)
OptionableNot Optionable
Heska (NASDAQ:HSKA) Frequently Asked Questions
What is Heska's stock symbol?
Heska trades on the NASDAQ under the ticker symbol "HSKA."
How were Heska's earnings last quarter?
Heska Corp (NASDAQ:HSKA) announced its quarterly earnings data on Tuesday, August, 6th. The medical research company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.04. The medical research company earned $28.15 million during the quarter, compared to analyst estimates of $29.19 million. Heska had a return on equity of 6.35% and a net margin of 1.93%. View Heska's Earnings History.
When is Heska's next earnings date?
What price target have analysts set for HSKA?
5 equities research analysts have issued twelve-month price objectives for Heska's stock. Their predictions range from $75.00 to $87.00. On average, they anticipate Heska's stock price to reach $81.00 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View Analyst Price Targets for Heska.
What is the consensus analysts' recommendation for Heska?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Heska.
What are Wall Street analysts saying about Heska stock?
Here are some recent quotes from research analysts about Heska stock:
- 1. Canaccord Genuity analysts commented, "We view this financing as overdue" as the company had been operating for some time at a cash balance hovering around $10 million. We trim our out year revenue and earnings estimates as we exercise more conservatism on Heska’s top line growth, and we expect a higher level of spending to help return the company to growth, following ~3 years of missing expectations. We are cautiously optimistic to see Heska deliver on its growth initiatives, however, our near-term expectations are tempered until we see evidence of stronger commercial execution. While we trim our estimates and price target to $75 (from $95), we are sticking with our BUY rating in hopes we see progress on new product and geographic expansion as we look out to 2020. Convertible notes." (9/12/2019)
- 2. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (3/5/2019)
Has Heska been receiving favorable news coverage?
News articles about HSKA stock have trended negative on Tuesday, according to InfoTrie. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Heska earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Heska.
Who are some of Heska's key competitors?
Some companies that are related to Heska include Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), GeneNews (GNWSF) and Arca Biopharma (ABIO).
What other stocks do shareholders of Heska own?
Who are Heska's key executives?
Heska's management team includes the folowing people:
- Mr. Kevin S. Wilson, CEO, Pres & Director (Age 47)
- Mr. Jason A. Napolitano, COO & Chief Strategist (Age 51)
- Ms. Catherine I. Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 43)
- Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 56)
- Mr. Jason D. Aroesty, Exec. VP of International Diagnostics (Age 44)
Who are Heska's major shareholders?
Heska's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.77%), Vanguard Group Inc. (5.75%), Riverbridge Partners LLC (3.89%), Janus Henderson Group PLC (2.33%), Janus Henderson Group PLC (2.33%) and Granite Investment Partners LLC (2.16%). Company insiders that own Heska stock include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, Kevin S Wilson, Michael J Mcginley, Nancy Wisnewski, Rod Lippincott, Scott Humphrey, Steve Asakowicz and Steven M Eyl. View Institutional Ownership Trends for Heska.
Which institutional investors are selling Heska stock?
HSKA stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Invesco Ltd., Riverbridge Partners LLC, Wells Fargo & Company MN, CIBC Private Wealth Group LLC, Grace & White Inc. NY, Bank of America Corp DE and State Board of Administration of Florida Retirement System. Company insiders that have sold Heska company stock in the last year include G Irwin Gordon, Jason A Napolitano and Kevin S Wilson. View Insider Buying and Selling for Heska.
Which institutional investors are buying Heska stock?
HSKA stock was bought by a variety of institutional investors in the last quarter, including Grandeur Peak Global Advisors LLC, Nine Ten Capital Management LLC, Nuveen Asset Management LLC, Eversept Partners LP, JPMorgan Chase & Co., Morgan Stanley, Allianz Asset Management GmbH and Royal Bank of Canada. View Insider Buying and Selling for Heska.
How do I buy shares of Heska?
Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Heska's stock price today?
One share of HSKA stock can currently be purchased for approximately $69.98.
How big of a company is Heska?
Heska has a market capitalization of $545.63 million and generates $127.45 million in revenue each year. The medical research company earns $5.85 million in net income (profit) each year or $1.42 on an earnings per share basis. Heska employs 347 workers across the globe.View Additional Information About Heska.
What is Heska's official website?
How can I contact Heska?
Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]
MarketBeat Community Rating for Heska (NASDAQ HSKA)
MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days.
